Why the study?
Does rivaroxaban safely and effectively treat and prevent recurrent venous thromboembolism compared to standard therapy in patients with DVT or PE?
Does rivaroxaban safely and effectively treat and prevent recurrent venous thromboembolism compared to standard therapy in patients with DVT or PE?
Hazard Ratio: 1.12 (95% CI 0.75–1.68)
Absolute Event Rate: 2.1% vs 1.8%
p-value: p=0.57
Rivaroxaban provides an effective and safer oral alternative to standard LMWH/VKA therapy for the treatment of pulmonary embolism, though caution is needed in specific high-risk populations.
May support rivaroxaban as oral option in PE; leaves open optimal use in high-bleeding-risk subgroups.
With the advent of new oral anticoagulants (NOACs) for the treatment of deep-vein thrombosis (DVT) and/or pulmonary embolism (PE), a new era of oral anticoagulation for patients with venous thromboembolism (VTE) has begun. Rivaroxaban is the first NOAC to receive regulatory approval for the acute and continued treatment of DVT and PE, and for the secondary prevention of VTE. Here, the clinical trials of rivaroxaban in patients with VTE are reviewed, and the clinical use of rivaroxaban for patients with PE is discussed. Even though rivaroxaban will facilitate the therapeutic management of PE, its use in specific clinical situations needs further study.
No takes yet. Share an insight, caveat, or question.
Vanassche et al. (2013) conducted a review in Pulmonary Embolism (n=4,832). Rivaroxaban vs. Enoxaparin/VKA therapy was evaluated on Recurrent VTE (HR 1.12, 95% CI 0.75-1.68, p=0.57).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: